The best frequency of monitoring to detect the onset or progression of lung disease in patients with AATD has yet to be established and depends on serum AAT concentration and pathogenicity of the mutation presented. This evidence concerns the gene SERPINA1 and alpha 1-antitrypsin deficiency.